Cobra Biomanufacturing Wins New Adenovirus Service Contract

Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has signed an agreement with a European biotechnology company to provide development services for an Adenovirus based product. Cobra was selected because of its experience with Adenovirus production and the full production service that Cobra can provide.

At the heart of the contract will be the application of Cobra's proprietary virus purification platform, which is based on scalable chromatographic operations and integrates single use technologies throughout. The process shows comparable purities to density gradient approaches and yields of up to 50%.

Simon Saxby, Chief Executive of Cobra Biomanufacturing said:

"We are very pleased to have been selected by this company as this underlines Cobra's extensive experience and expertise in producing virus based products for clinical trials. This agreement also highlights Cobra's continued commitment to be the CMO of choice for virus production."

SOURCE: Cobra Biomanufacturing Plc